This bid is closed — responses were due June 3, 2026.
It is no longer accepting submissions. We keep closed bids on BidsNexus for reference: agencies often re-issue the same need, and past bids show what they buy and when.
This bid is for the modification of an existing A11 HERV-E TCR and T cell product to enhance its therapeutic effectiveness for patients with clear cell renal cell carcinoma (ccRCC). The government intends to sole source this requirement.
Line Items
Item
Qty
Unit
Est. Unit Price
Est. Total
Category
Modification of A11 HERV-E TCR and T cell product
1
lot
$500,000.00
$500,000.00
Medical
Estimated Bid Value
$500,000.00
Want the full details?
Sign up free to see the agency name and the original bid posting link. Pro adds the 1 document, contracting-officer contacts and AI response outlines.